Published in Gastroenterol Clin Biol on January 01, 1990
Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor. World J Surg Oncol (2007) 1.15
Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case. Surg Today (2010) 0.91
Collision tumour of the oesophagus: a challenge for histological diagnosis. J Clin Pathol (1996) 0.85
Collision tumor of low-grade B-cell lymphoma and adenocarcinoma with tuberculosis in the colon: a case report and literature review. World J Surg Oncol (2014) 0.77
Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review. Oncol Lett (2016) 0.75
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med (1994) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2000) 2.04
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant (2011) 1.75
Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant (2009) 1.65
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia (2004) 1.62
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol (2010) 1.42
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
Experimental reduction of portal hypertension by mechanical increase of liver portal flow. Lancet (1991) 1.40
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Choledocho-ureteral anastomosis in the rat. A new experimental model of long-term, total, internal bile diversion. J Hepatol (1993) 1.39
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology (1996) 1.28
Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest (2001) 1.27
Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol (1994) 1.26
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat (2011) 1.24
A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab (2003) 1.20
Fetal microchimerism in primary biliary cirrhosis. J Hepatol (2000) 1.20
Dzyaloshinski-Moriya interaction in the 2D spin gap system SrCu(2)(BO(3))(2). Phys Rev Lett (2001) 1.12
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology (1993) 1.12
Pharmacological effect of somatostatin on bile secretion in man. Digestion (1989) 1.11
Chronic cholestatic diseases. J Hepatol (2000) 1.11
Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis (2008) 1.11
Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse. Hepatology (2001) 1.11
The superoxide dismutase mimetic MnTBAP prevents Fas-induced acute liver failure in the mouse. Gastroenterology (2001) 1.07
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther (1990) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol (1990) 1.00
Internal bioartificial liver with xenogeneic hepatocytes prevents death from acute liver failure: an experimental study. Ann Surg (1998) 0.99
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology (2006) 0.96
Bile acid transport and regulating functions in the human biliary epithelium. Hepatology (2001) 0.95
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat (1995) 0.94
Effect of lysine acetylsalicylate on biliary lipid secretion in dogs. Clin Sci Mol Med (1975) 0.93
APRI and FIB-4 Scores Are Useful After Liver Transplantation Independently of Etiology. Transplant Proc (2009) 0.93
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology (1996) 0.92
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
[Celiac disease in adults. (48 cases) I. Anatomo-clinical, biological and radiological study; its course under a non-gluten diet]. Arch Fr Mal App Dig (1975) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation. J Hepatol (1997) 0.89
Impact of screening donor blood for alanine aminotransferase and antibody to hepatitis B core antigen on the risk of hepatitis C virus transmission. Eur J Clin Microbiol Infect Dis (1993) 0.88
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology (1997) 0.88
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology (1998) 0.88
Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology (1990) 0.88
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology (2001) 0.88
Elastography in hepatology. Can J Gastroenterol (2007) 0.87
Endothelin-1 secretion by human gallbladder epithelial cells in primary culture. Lab Invest (1993) 0.87
Comparison between aortic and sinusoidal liver endothelial cells as targets of hyperacute xenogeneic rejection in the pig to human combination. Transplantation (1996) 0.87
Comparison of a new method for the direct and simultaneous assessment of LDL- and HDL-cholesterol with ultracentrifugation and established methods. Clin Chem (2000) 0.87
Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology (1995) 0.87
Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant (2009) 0.87
Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther (1988) 0.86
Permeability and biocompatibility of a new hydrogel used for encapsulation of hepatocytes. Biomaterials (1995) 0.86
Increase in monocyte procoagulant activity with age. Thromb Res (1986) 0.86
Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology (1992) 0.86
A reversible model of acute hepatic failure by temporary hepatic ischemia in the pig. J Surg Res (2000) 0.85
Bile acids modulate the interferon signalling pathway. Hepatology (1999) 0.85